Literature DB >> 23083826

Future classes of hepatitis C virus therapeutic agents.

Jennifer Y Chen1, Raymond T Chung.   

Abstract

Recent advances in understanding of the molecular characteristics of the hepatitis C virus have led to the development of novel antiviral therapeutics. Direct-acting antivirals are designed to inhibit viral targets, whereas host-targeted antivirals block host factors that are used by the virus for its own life cycle. The rapid development of agents in multiple classes has led to the promise of shorter therapy duration, an improved side effect profile, and eventually interferon-sparing regimens. This article reviews novel hepatitis C virus therapeutics in development, including mechanism of action, efficacy, and adverse effects. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23083826      PMCID： PMC4624290          DOI： 10.1016/j.idc.2012.08.003

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  60 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Unique ties between hepatitis C virus replication and intracellular lipids.

Authors:  Eva Herker; Melanie Ott
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

3.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

4.  Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes.

Authors:  Pauline Ferraris; Emmanuelle Blanchard; Philippe Roingeard
Journal:  J Gen Virol       Date:  2010-05-19       Impact factor: 3.891

5.  Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.

Authors:  Lee F Peng; Esperance A K Schaefer; Nicole Maloof; Andrew Skaff; Andrew Berical; Craig A Belon; Julie A Heck; Wenyu Lin; David N Frick; Todd M Allen; Henry M Miziorko; Stuart L Schreiber; Raymond T Chung
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

7.  The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

Authors:  Robert Flisiak; Saya V Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryczka; Małgorzata Pawlowska; Jenny E Heathcote; Giuseppe Mazzella; Carmen Vandelli; Valérie Nicolas-Métral; Pierre Grosgurin; Jorge S Liz; Pietro Scalfaro; Hervé Porchet; Raf Crabbé
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

8.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

9.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

10.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.